Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HCM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ranosidenib (HMPL-306) | Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation | Phase 3 · NCT07912398 | Not yet recruiting |
| BTK Inhibitor HMPL-760 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 3 · NCT07409428 | Recruiting |
| Salvage Chemotherapy Regimen | Acute Myeloid Leukemia | Phase 3 · NCT06387069 | Recruiting |
| Sovleplenib (HMPL-523) | Warm Antibody Autoimmune Hemolytic Anemia | Phase 2/3 · NCT05535933 | Active not recruiting |
| Savolitinib | Non-small Cell Lung Cancer | Phase 3 · NCT05009836 | Active not recruiting |
| Sintilimab | Advanced Endometrial Cancer | Phase 3 · NCT06584032 | Recruiting |
| Fanregratinib (HMPL-453) | Advanced Intrahepatic Cholangiocarcinoma | Phase 2/3 · NCT04353375 | Recruiting |
| Camrelizumab | Metastatic Pancreatic Cancer | Phase 2/3 · NCT06361888 | Recruiting |
| Surufatinib | Metastatic Pancreatic Cancer | Phase 2/3 · NCT06361888 | Recruiting |
| Osimertinib | Non-small Cell Lung Cancer | Phase 3 · NCT05009836 | Active not recruiting |
| Doxorubicin | Advanced Endometrial Cancer | Phase 3 · NCT06584032 | Recruiting |
| Nab-paclitaxel | Metastatic Pancreatic Cancer | Phase 2/3 · NCT06361888 | Recruiting |
| Pamiparib | Ovarian Cancer | Phase 1/2 · NCT05494580 | Completed |
| Anti-EGFR Antibody-PI3K/PIKK Inhibitor… | Solid Tumors, Adult | Phase 1/2 · NCT07396584 | Recruiting |
| Anti-HER2 Antibody-PI3K/PIKK Inhibitor… | Solid Tumors, Adult | Phase 1/2 · NCT07228247 | Recruiting |
| Amdizalisib (HMPL-689) | Relapsed/Refractory Lymphoma | Phase 2 · NCT05713110 | Completed |
Also used in these trials (approved or third-party drugs, not HCM's own candidates): Rituximab, Paclitaxel, Fruquintinib, Axitinib, Tazemetostat, Tislelizumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
HCM holds $1.4B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HCM files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Wei-guo Su CEO and CSO, Director · +208,004 options |
Insider | 237,063 | 0.03% | 2026-03-16 |
| Edith Shih Director |
Insider | 100,000 | 0.01% | 2026-03-10 |
| Chig Fung Cheng Acting CEO and CFO, Director · +56,464 options |
Insider | 56,693 | 0.01% | 2026-03-11 |
| Charles George Rupert Nixon Group General Counsel · +15,089 options |
Insider | 41,763 | 0.00% | 2026-03-31 |
| Tony Shu Kam Mok Former Director |
Insider | 27,341 | 0.00% | 2026-03-10 |
| Dan Eldar Director |
Insider | 26,332 | 0.00% | 2026-03-10 |
| Renu Bhatia Director |
Insider | 16,000 | 0.00% | 2026-03-10 |
| Lorenso Chiu Deputy Chief Financial Officer · +14,039 options |
Insider | 8,475 | 0.00% | 2026-03-18 |
Share count 872,327,620 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →